Table 2 Characteristics of chronic GVHD.
Variable | Level | ECP (n = 84) | Ruxo(n = 57) | Overall (n = 141) | P-value |
|---|---|---|---|---|---|
Type of steroid | Prednisone | 69 (82.1%) | 42 (73.7%) | 111 (78.7%) | Not done |
Methylprednisone | 15 (17.9%) | 15 (26.3%) | 30 (21.3%) | ||
Steroid initial dose (mg/kg/day) | median (min-max) [IQR] | 1 (0.1-80) [0.5-1] | 1 (0.1-2) [0.4-1] | 1 (0.1-80) [0.5-1] | Not done |
missing | 1 | 2 | 3 | ||
Time between start and end of steroids (days) | median (min-max) [IQR] | 239 (3-1028) [93.8-474.8] | 196 (3-1709) [95.2-391.8] | 218.5 (3-1709) [93.8-411.2] | Not done |
missing | 22 | 17 | 39 | ||
Other systemic drugs or strategies used to treat aGvHD (other than steroids) | No other drugs / strategies | 27 (32.1%) | 18 (31.6%) | 45 (31.9%) | Not done |
CNI | 32 (38.1%) | 25 (43.9%) | 57 (40.4% | ||
MMF | 18 (21.4%) | 14 (24.6%) | 32 (22.7%) | ||
Others # | 10 (11.9%) | 8 (14%) | 18 (12.7%) | ||
Time start steroids to SR onset (days) | median (min-max) [IQR] | 78 (0-543) [23-196.8] | 126 (0-1037) [41-370.2] | 94 (0-1037) [28-237] | Not done |
Type of steroid refractory | Steroid-dependant | 34 (40.5%) | 13 (22.8%) | 47 (33.3%) | 0.038 |
Steroid-intolerant | 13 (15.5%) | 17 (29.8%) | 30 (21.3%) | ||
Steroid-refractory | 37 (44%) | 27 (47.4%) | 64 (45.4%) | ||
Chronic GVHD overall grade (at start of SR treatment) | Moderate | 30 (35.7%) | 21 (36.8%) | 51 (36.2%) | |
Severe | 54 (64.3%) | 36 (63.2%) | 90 (63.8%) | 0.89 | |
Skin NIH score (at start of SR treatment) | 0 | 18 (22%) | 16 (29.1%) | 34 (24.8%) | |
1 | 19 (23.2%) | 7 (12.7%) | 26 (19%) | Not done | |
2 | 21 (25.6%) | 12 (21.8%) | 33 (24.1%) | ||
3 | 24 (29.3%) | 20 (36.4%) | 44 (32.1%) | ||
missing | 2 | 2 | 4 | ||
Liver NIH score (at start of SR treatment) | 0 | 53 (65.4%) | 36 (64.3%) | 89 (65%) | |
1 | 11 (13.6%) | 11 (19.6%) | 22 (16.1%) | Not done | |
2 | 8 (9.9%) | 6 (10.7%) | 14 (10.2%) | ||
3 | 9 (11.1%) | 3 (5.4%) | 12 (8.8%) | ||
missing | 3 | 1 | 4 | ||
Lower GI NIH score (at start of SR treatment) | 0 | 61 (77.2%) | 41 (73.2%) | 102 (75.6%) | |
1 | 4 (5.1%) | 6 (10.7%) | 10 (7.4%) | ||
2 | 6 (7.6%) | 3 (5.4%) | 9 (6.7%) | Not done | |
3 | 8 (10.1%) | 6 (10.7%) | 14 (10.4%) | ||
missing | 5 | 1 | 6 | ||
Upper GI NIH score (at start of SR treatment) | 0 | 70 (88.6%) | 47 (85.5%) | 117 (87.3%) | |
1 | 3 (3.8%) | 6 (10.9%) | 9 (6.7%) | Not done | |
2 | 3 (3.8%) | 1 (1.8%) | 4 (3%) | ||
3 | 3 (3.8%) | 1 (1.8%) | 4 (3%) | ||
missing | 5 | 2 | 7 | ||
Mouth NIH score (at start of SR treatment) | 0 | 33 (41.2%) | 13 (23.2%) | 46 (33.8%) | |
1 | 25 (31.2%) | 21 (37.5%) | 46 (33.8%) | Not done | |
2 | 17 (21.2%) | 15 (26.8%) | 32 (23.5%) | ||
3 | 5 (6.2%) | 6 (10.7%) | 11 (8.1%) | ||
missing | 4 | 2 | 6 | ||
Eyes NIH score (at start of SR treatment) | 0 | 49 (63.6%) | 28 (50.9%) | 77 (58.3%) | |
1 | 14 (18.2%) | 10 (18.2%) | 24 (18.2%) | ||
2 | 12 (15.6%) | 9 (16.4%) | 21 (15.9%) | Not done | |
3 | 2 (2.6%) | 7 (12.7%) | 9 (6.8%) | ||
missing | 7 | 2 | 9 | ||
Lung NIH score (at start of SR treatment) | 0 | 61 (79.2%) | 43 (78.2%) | 104 (78.8%) | |
1 | 5 (6.5%) | 4 (7.3%) | 9 (6.8%) | ||
2 | 8 (10.4%) | 5 (9.1%) | 13 (9.8%) | Not done | |
3 | 3 (3.9%) | 3 (5.5%) | 6 (4.5%) | ||
missing | 7 | 2 | 9 |
